Dr. Kay Discusses the Role of Ibrutinib in CLL

Video

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Once a patient relapses after primary therapy, their responses are short-lived based on data from prior clinical trials. With newer drugs such as ibrutinib or venetoclax (Venclexta), which are FDA approved for patients with relapsed/refectory CLL, there is less emphasis on prognostic factors, explains Kay. However, it is important to know the parameters of the treatment.

If a patient has relapsed and is shown to have 17p deletion via fluorescence in situ hybridization, they would respond well to these agents, says Kay, but their responses would be less robust if they did not have the defect. The current progression-free survival (PFS) for patients receiving ibrutinib with 17p deletion is around 26 months, whereas for the more favorable groups, the PFS has not been reached. This is an improvement over prior drugs, but having that genetic defect may not allow for a long response, he explains.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute